Medpace (MEDP)
(Delayed Data from NSDQ)
$390.91 USD
+4.59 (1.19%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $390.50 -0.41 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$390.91 USD
+4.59 (1.19%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $390.50 -0.41 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
Why Teladoc (TDOC) Stock Has More Than Doubled in a Year
by Zacks Equity Research
Teladoc (TDOC) continues to gain from high demand for its telehealth services.
4 Health Care Stocks Set to Beat Earnings Estimates in 4Q
by Zacks Equity Research
This attractive sector has several companies with upside potential.
Zacks.com featured expert Kevin Matras highlights: M.D.C., Ruth???s Hospitality, Medpace and Xylem
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: M.D.C., Ruth???s Hospitality, Medpace and Xylem
Winning Stock Picks from the Top 4 Industries with the Biggest Job Growth
by Kevin Matras
Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include MDC, RUTH, MEDP and XYL.
Will Higher Membership, Revenues Aid Cigna (CI) Q4 Earnings?
by Zacks Equity Research
Cigna's (CI) Q4 earnings should likely be aided by higher revenues from its healthcare, global supplement units, partly offset by Medicare membership loss.
DaVita (DVA) Partners with Epic to Launch EHR for Patients
by Zacks Equity Research
DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.
New Strong Buy Stocks for December 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
AmerisourceBergen (ABC) Q4 Earnings: Will it Disappoint?
by Zacks Equity Research
The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen's (ABC) bottom line in the fourth quarter
Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.
Ecolab (ECL) to Report Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
Ecolab's (ECL) large base of recurring revenues, industry-leading technologies and excellent field service are propellers. However, the company faces cut-throat competition in the niche space.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.
Will Higher System Sales Drive Cerner's (CERN) Q3 Earnings?
by Zacks Equity Research
Strong growth in licensed software and subscriptions are expected to be the main factors driving systems revenues for Cerner (CERN) in the third quarter of 2017.
Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.
Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.
PAREXEL's Acquisition by Pamplona Approved by Shareholders
by Zacks Equity Research
The long-awaited PAREXEL (PRXL) acquisition by Pamplona Capital Management finally receives shareholders' approval. Moreover, the company plans to go private post-acquisition.
4 Momentum Stocks to Pick Despite MedTech Policy Debacle
by Zacks Equity Research
Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.
Teladoc (TDOC) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
HCA Healthcare Rides on Acquisitions, Weak Volumes Bother
by Zacks Equity Research
A number of acquisitions have added facilities and widened network at HCA Healthcare (HCA). Weak admissions, however, continue to bother.
Healthcare Q2 Earnings Set to Release on Jul 31: HLS, MEDP
by Zacks Equity Research
The Healthcare sector's earnings will be driven by continued efforts by the players to provide high-quality, cost-effective care, partly offset by rising medical and operating costs.
What Falling Estimates & Price Mean for Medpace Holdings (MEDP)
by Zacks Equity Research
Medpace Holdings, Inc. (MEDP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Healthcare Q1 Earnings to Watch on May 1: THC, MEDP, CYH
by Zacks Equity Research
So far, 33.3% of the total Medical sector companies have reported first-quarter results.